**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 81807

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Comprehensive analysis of prognostic value and immunotherapy prospect of brain cytoplasmic RNA1 in hepatocellular carcinoma**

Han XY *et al*. *BCYRN1* in hepatocellular carcinoma

Xiao-Yong Han, Xiong Li, Rang-Yin Zhao, Hai-Zhong Ma, Miao Yu, Xiang-Dong Niu, Hao-Jie Jin, Yong-Feng Wang, De-Ming Liu, Hui Cai

**Xiao-Yong Han, Xiong Li, Rang-Yin Zhao, Hai-Zhong Ma, Miao Yu, Xiang-Dong Niu, Yong-Feng Wang, De-Ming Liu, Hui Cai,** Gansu General Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China

**Xiao-Yong Han, Xiong Li,** Graduate School, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China

**Xiao-Yong Han, Miao Yu, Yong-Feng Wang, Hui Cai,** Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China

**Rang-Yin Zhao,** The First Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, China

**Hai-Zhong Ma, Hao-Jie Jin, Yong-Feng Wang,** The First Clinical College of Medicine, Lanzhou University, Lanzhou 730000, Gansu Province, China

**Hui Cai,** Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou 730000, Gansu Province, China

**Hui Cai,** NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China

**Author contributions:** Han XY conceived the study; Zhao RY, Niu XD and Jin HJ performed the download and analysis of data; Yu M, Liu DM and Wang YF performed visual drawings; Han XY and Li X co-wrote the manuscript; Ma HZ and Cai H reviewed this manuscript; Han XY and Li X contributed equally to this work.

**Supported by** the 2021 Central-Guided Local Science and Technology Development Fund, No. ZYYDDFFZZJ-1; Gansu Key Laboratory of Molecular Diagnosis and Precision Treatment of Surgical Tumors, No. 18JR2RA033; Key Laboratory of Gastrointestinal Cancer Diagnosis and Treatment of National Health Commission, No. 2019PT320005; Key Talent Project of Gansu Province of the Organization Department of Gansu Provincial Party Committee, No. 2020RCXM076; Guiding Plan for Scientific and Technological Development of Lanzhou, No. 2019-ZD-102.

**Corresponding author: Hui Cai, PhD, Research Scientist, Researcher,** Gansu General Surgery Clinical Medical Center, Gansu Provincial Hospital, No. 204 Donggang West Road, Chengguan District, Lanzhou 730000, Gansu Province, China. caialonteam@163.com

**Received:** November 24, 2022

**Revised:** February 18, 2023

**Accepted:** March 15, 2023

**Published online:**

**Abstract**

BACKGROUND

The expression of brain cytoplasmic RNA1 (*BCYRN1*) is linked to the clinicopathology and prognosis of several types of cancers, among which hepatocellular carcinoma (HCC) is one of the most frequent types of cancer worldwide.

AIM

To explore the prognostic value and immunotherapeutic potential of *BCYRN1* in HCC by bioinformatics and meta-analysis.

METHODS

Information was obtained from the Cancer Genome Atlas database. First, the correlation between *BCYRN1* expression and prognosis and clinicopathologic characteristics of HCC patients was explored. Univariate and multivariate regression analyses were employed to examine the relationship between *BCYRN1* and HCC prognosis. Secondly, potential functions and pathways were explored by means of enrichment analysis of differentially-expressed genes. The relationships between *BCYRN1* expression and tumor microenvironment, immune cell infiltration, immune checkpoint, drug sensitivity and immunotherapy effect were also investigated. Finally, three major databases were searched and used to conduct a meta-analysis on the relationship between *BCYRN1* expression and patient prognosis.

RESULTS

*BCYRN1* expression was significantly higher in HCC compared to normal tissues and was linked to a poor prognosis and clinicopathological characteristics. Enrichment analysis showed that *BCYRN1* regulates the extracellular matrix and transmission of signaling molecules, participates in the metabolism of nutrients, such as proteins, and participates in tumor-related pathways. *BCYRN1* expression was linked to the tumor microenvironment, immune cell infiltration, drug sensitivity and the efficacy of immunotherapy. Furthermore, the meta-analysis in this study showed that *BCYRN1* overexpression was related to a worse outcome in HCC patients.

CONCLUSION

Overexpression of *BCYRN1* relates to poor prognosis and may be a potential prognostic factor and immunotherapeutic target in HCC.

**Key Words:** Brain cytoplasmic RNA1; Immunotherapy; Prognostic; Biomarker; Hepatocellular carcinoma

Han XY, Li X, Zhao RY, Ma HZ, Yu M, Niu XD, Jin HJ, Wang YF, Liu DM, Cai H. Comprehensive analysis of prognostic value and immunotherapy prospect of brain cytoplasmic RNA1 in hepatocellular carcinoma. *World J Gastrointest Oncol* 2023; In press

**Core Tip:** In this study, we combined the research methods of meta-analysis and bioinformatics analysis to comprehensively analyze and explore the prognostic value of brain cytoplasmic RNA1 (*BCYRN1*) in hepatocellular carcinoma (HCC) and the prospects of immunotherapy. Our study found that overexpression of *BCYRN1* was significantly associated with poor prognosis in HCC patients and may be an independent prognostic factor for HCC and a target for immunotherapy.

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is one of the most common types of cancer worldwide and has a high mortality rate[1]. Relevant statistics have shown that the number of new liver cancer cases worldwide was about 9 million in the year 2020, of which the most common type was HCC. HCC is the third-leading cause of cancer-related deaths worldwide, with a 5-year survival rate of less than 20%[2,3]. Early detection of HCC can achieve a good 5-year survival rate by surgical treatment[4], liver transplantation and radiotherapy. However, the symptoms of patients with early HCC are not apparent. Therefore, most patients are diagnosed in the advanced stage. Since only systemic chemotherapy can delay progression, the prognosis is very poor[5]. Therefore, early diagnosis and treatment is particularly important. Identifying novel sensitive tumor markers and discovering novel molecular therapeutic targets are key goals, and exploring novel immunotherapeutic drugs is another breakthrough[6,7].

With the progress of high-throughput sequencing technology, research on long non-coding RNA (lncRNA) has developed rapidly in the field of bioinformatics, especially in oncology[8]. LncRNAs are generally longer than 200 nucleotides and do not encode proteins[9]. An increasing number of studies have shown that lncRNAs can influence gene expression at translational and transcriptional levels by chromatin remodeling, affecting RNA splicing and controlling the transmission of signaling pathways[10,11]. In addition, lncRNA affects tumor and immune cell metabolism, remodeling of the immune microenvironment and promoting carcinogenesis[12]. Abnormal expression of lncRNAs can affect biological processes, including tumor cell growth, migration, invasion, angiogenesis and metastasis, which are linked to the occurrence and prognosis of various types of cancer and has a broad research prospect[13,14].

Brain cytoplasmic RNA1 (*BCYRN1*), also known as brain cytoplasmic 200 (BC200), is mainly present in neurons, and abnormal expression of *BCYRN1* is associated with neurodegenerative diseases and malignant tumors[15]. It has previously been shown that compared with surrounding normal tissues, *BCYRN1* is overexpressed in a number of cancer types[16,17], including gastric cancer[18,19], bladder cancer[20,21], colorectal cancer[22-25] and HCC[26-28]. Furthermore, *BCYRN1* overexpression is closely related to poor patient prognosis[15]. Therefore, *BCYRN1* is a potential cancer therapeutic target and tumor prognostic marker[29]. To further clarify the prognostic value of *BCYRN1* in HCC and the prospects of immunotherapy, data related to HCC was obtained from the Cancer Genome Atlas (TCGA), and bioinformatics analysis was performed. First, expression levels of *BCYRN1* were explored in normal liver tissues and HCC and differences in survival prognosis between the low and high expression groups of *BCYRN1* were analyzed. Second, the relationship between the *BCYRN1* expression level and clinicopathologic characteristics in HCC patients was investigated. Univariate and multivariate Cox regression analysis and nomogram prognostic models for HCC were performed. In addition, co-expressed genes and differentially expressed genes (DEGs) related to *BCYRN1* were screened, and enrichment analysis was employed to further investigate the possible pathways and functions of *BCYRN1*. The correlations between *BCYRN1* expression and tumor microenvironment (TME), immune cell infiltration, immune checkpoints, tumor mutation burden (TMB), chemosensitivity and immunotherapy efficacy were investigated. Finally, to validate the prognostic value of *BCYRN1* in HCC, a relevant literature search and meta-analysis were performed.

**MATERIALS AND METHODS**

***Data download***

Gene expression data and information on clinical features from 50 normal tissue samples and 374 liver hepatocellular carcinoma (LIHC) samples were obtained from the TCGA database (<https://portal.gdc.cancer.gov/>). Subsequent analyses and mapping were performed on this dataset. Because the TCGA database is freely accessible, ethics committee approval was not required for this study.

***Expression of BCYRN1 in pan-carcinoma and HCC***

A uniformly normalized pan-cancer dataset was downloaded using the University of California Santa Cruz database (<https://xenabrowser.net/>), expression information of *BCYRN1* in every sample was obtained, and the expression difference plots of *BCYRN1* in pan-cancer was mapped through the online bioinformatics analysis website Sangerbox (<http://sangerbox.com/>, based on TCGA and GTEx databases). R software (R 4.1.3 version) was utilized to analyze the expression differences of *BCYRN1* in HCC using R packages “limma,” “ggplot2” and “ggpubr.” Boxplots were plotted, and difference plots of expression differences were paired.

***Association between BCYRN1 expression and HCC patient survival prognosis***

The online database GEPIA2 (<http://gepia2.cancer-pku.cn>) was used to evaluate the relationship between *BCYRN1* gene expression levels and survival prognosis of HCC patients. Second, the data downloaded from TCGA were analyzed using the “survival” and “survminer” R packages, and Kaplan-Meier (KM) curves were plotted to show the association of *BCYRN1* expression with progression-free survival (PFS) and overall survival (OS). Finally, receiver operating characteristic (ROC) curves were plotted to assess the predictive value of *BCYRN1* expression for different prognosis years using the “timeROC” R package.

***Association between BCYRN1 and clinicopathologic features of HCC***

The associations between *BCYRN1* and HCC clinicopathology (age, gender, tumor stage, T stage, M stage, histological grade) were analyzed using the “limma” and “ggpubr” R packages using previously downloaded clinical information from the TCGA database. Finally, a heatmap of clinical relevance was plotted using the R package “ComplexHeatmap.”

***Analysis of independent prognostic factors and establishment of prognostic model***

First, the R package “survival” was used to accomplish univariate regression analysis and multivariate COX regression analysis of the expression of *BCYRN1* with clinicopathological information and survival information of HCC patients. Then, forest plots were drawn to determine independent prognostic indicators of HCC. Second, the R packages “survival,” “rms” and “regplot” were used to summarize the clinical and prognostic information of patients. Nomograms were drawn to predict 5-year, 3-year and 1-year OS rates of HCC patients. To evaluate the accuracy of the prediction model, a calibration curve of the nomogram was drawn.

***Gene co-expression and grouping DEG analysis of BCYRN1***

In this study, co-expression analysis was performed using the “Pearson” method with four R packages, “limma,” “ggplot2,” “ggpubr” and “ggExtra.” A certain index was set to screen focused co-expressed genes (correlation coefficient > 0.5, *P* < 0.001) after which visual analysis was performed. Twelve genes with the strongest correlation were selected from the co-expressed genes, and the co-expression circles were plotted using the “circlizeand” and “corrplot” R packages. Finally, *BCYRN1* expression was divided into low and high expression groups using the R package “limma,” and screening conditions were set (false discovery rate < 0.05 and log2 foldchange > 1). Next, the DEGs in the groups were screened, and 50 upregulated and downregulated genes were selected, visualized using the “pheatmap” R package. A heat map of differential expression was drawn.

***Enrichment analysis of BCYRN1-associated DEGs***

To explore the possible enriched signaling pathways and related functions, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of *BCYRN1*-related DEGs were conducted using a series of R packages (“clusterProfile,” “org.Hs.eg.db,” “circlize,” “RColorBrewer,” “enrichplot,” “dplyr,” “ComplexHeatmap”). The filter condition *P* value filter was set to 0.05. In this process, a histogram, bubble diagram and GO circle diagram were drawn. Finally, the possible enriched functions and pathways of *BCYRN1*-associated DEGs were further explored using HCC using Gene Set Enrichment Analysis (GSEA).

***Correlation analysis between BCYRN1 expression in HCC and TME and immune cell infiltration***

Previously downloaded HCC-related expression data were entered, the scores of immune cells and stromal cells of HCC-related samples were calculated utilizing the “limma” and “estimate” R package, and the scores of the two cells were added to obtain a comprehensive score “ESTIMATEScore.” The “reshape2” and “ggpubr” R packages were used to plot the resulting TME scores into violin plots for TME difference analysis between low and high *BCYRN1* expression groups. The R packages “limma” and “CIBERSORT” were used to compute the percentage composition of 22 immune cells in each sample. Next, the “reshape2,” “vioplot” and “ggExtra” R packages were used to draw boxplots and correlation scatterplots of immune cell differences. Finally, lollipops were plotted according to the sorted correlation results.

***Correlation analysis between BCYRN1 and immune checkpoint genes and TMB***

Immune checkpoint genes associated with *BCYRN1* were selected using the “reshape2,” “ggplot2,” “ggpubr” and “corrplot” R packages. A correlation coefficient of *P* < 0.001 was set as the screening filter based on the downloaded gene expression data and immune checkpoint-related gene lists of HCC samples, and circular correlation heat maps and rectangular correlation heat maps were plotted, respectively. Then, the R package “ggExtra” was utilized to explore the correlation between the expression of *BCYRN1* and TMB based on genetic tumor mutation load files, and scatter plots of the correlation were drawn.

***Correlation analysis of BCYRN1 expression with drug sensitivity and immunotherapy***

The R package “pRRophetic” was utilized to compute the half-maximal inhibitory concentration (IC50) of the drug based on downloaded gene expression data, and *P* = 0.001 was set as a filtering condition. Next, the calculation results were visualized as a difference boxplot using the R packages “ggplot2” and “ggpubr”. The corresponding IC50 differences between the low and high *BCYRN1* expression groups were assessed from the boxplots to determine the sensitivity differences of anticancer drugs. Next, HCC-related immunotherapy-related data were downloaded from the Cancer Immunome Atlas database (<https://tcia.at/>). The scores of immunotherapy in the low and high expression groups of *BCYRN1* were analyzed using the “limma” and “ggpubr” R packages, and differential violin plots were drawn.

***Meta-analysis search strategy***

Searches were conducted as required by PRISMA guidelines[30]. With a cutoff date of October 2022, three English databases, Web of Science, PubMed, and Embase, were used to search for relevant studies on *BCYRN1* in HCC. The search keywords used were: (“BCYRN1” OR “BC200a” OR “LINC00004” OR “BC200” OR “Brain cytoplasmic RNA1”) AND (“Hepatocellular carcinoma” OR “HCC” OR “Liver cancer”). Two authors independently performed the search, and disagreements were resolved by discussion.

***Inclusion and exclusion criteria***

Inclusion criteria: (1) Patients diagnosed with HCC; (2) The target gene studied was *BCYRN1*; (3) The expression level of *BCYRN1* was detected by quantitative real-time polymerase chain reaction (qRT-PCR); and (4) According to the expression level of *BCYRN1* in HCC tissues, patients were separated into a low expression group and a high expression group. Survival hazard ratios (HRs) and the 95%CI were obtained by KM curves or multivariate regression analysis. Exclusion criteria: (1) Repeated studies; (2) The disease type was not HCC; (3) The target gene investigated was not *BCYRN1*; (3) The types of studies were reviews, meta-analyses, conference abstracts, letters and case reports; (4) Articles that did not focus on survival prognosis and focused on biological functions or mechanisms; and (5) Lack of HR or KM survival curves.

***Data extraction and quality evaluation of included literature***

The following information was extracted from the literature: first author’s name, country or region, publication time, sample size, method of RNA detection, cutoff values for high and low expression, source of HR values, HR with 95%CI and follow-up time. If the HR of *BCYRN1* was acquired by multivariate regression analysis in the study, it was extracted directly. Otherwise, it was indirectly derived by utilizing the Engauge Digitizer tool program from KM survival curves. Articles included were graded according to the Newcastle-Ottawa scale (NOS) and were considered eligible if they scored 6 or higher.

***Statistical analysis***

Stata12.0 software was used to analyze the extracted data. Forest plots were plotted to combine the extracted HR and 95%CI, and heterogeneity was assessed across studies by calculating *I*2 values. HR was combined using a fixed effects model if *I*2 was less than 50%, thereby indicating that no obvious heterogeneity existed between studies, and a random effects model if *I*2 was greater than or equal to 50%. Begg’s test was used to evaluate publication bias, and sensitivity analysis was performed to investigate the stability of the results. *P* < 0.05 was considered statistically significant.

**RESULTS**

***Differential expression analysis of BCYRN1 in pan-carcinoma and HCC***

*BCYRN1* expression was explored in pan-cancer, and it was discovered that *BCYRN1* expression was significantly higher in 17 tumor tissues compared to normal tissues, including breast invasive carcinoma (BRCA), lung adenocarcinoma (LUAD), esophageal cancer (ESCA), stomach and esophageal carcinoma (STES), stomach adenocarcinoma (STAD), lung squamous cell carcinoma (LUSC), LIHC, Wilms’ tumour (WT), skin cutaneous melanoma (SKCM), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), testicular germ cell tumors (TGCT), uterine carcinosarcoma (UCS), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (LAML), kidney chromophobe (KICH) and cholangiocarcinoma (CHOL). In contrast, *BCYRN1* expression was significantly lower in seven tumor tissues compared to normal tissues, including glioblastoma multiforme (GBM), glioma (GBMLGG), kidney renal papillary cell carcinoma (KIRP), pan-kidney cohort (KIPAN), kidney renal clear cell carcinoma (KIRC), thyroid carcinoma (THCA), and adrenocortical carcinoma (ACC) (Figure 1A). Then, *BCYRN1* expression was explored in HCC, and the difference analysis boxplot (Figure 1B) showed that *BCYRN1* expression in HCC tissues was significantly (*P* < 0.01) higher compared to that in normal liver tissues. These findings were consistent with the result of paired difference analysis of samples (*P* < 0.001) (Figure 1C).

***Correlation between prognosis and BCYRN1 expression in HCC patients***

The relationship between *BCYRN1* expression and the OS and disease-free survival (DFS) of HCC patients was investigated by the GEPIA2 database. The findings showed that overexpression of *BCYRN1* was associated with a worse OS (*P* = 0.0047; Figure 2A) and DFS (*P* = 0.0075; Figure 2B) in HCC patients. Based on the TCGA database, KM survival prognosis curves were drawn, and the results showed that patients with high expression of *BCYRN1* had a worse OS (*P* < 0.001; Figure 2C) and PFS (*P* = 0.025; Figure 2D). Finally, plotted ROC curves (Figure 2E) showed that the expression of *BCYRN1* was highly predictive for the 5-year prognosis of HCC patients.

***Correlation between BCYRN1 expression and clinicopathological characteristics of HCC patients***

By analyzing the connection between *BCYRN1* expression and the clinicopathological characteristics of HCC patients, it was discovered that *BCYRN1* expression was not significantly correlated with age (*P* = 0.26; Figure 3A), sex (*P* = 0.65; Figure 3B) and M stage (*P* = 0.17; Figure 3F) of patients. A significant correlation was observed with pathological grade (G1 *vs* G2 and G1 *vs* G3, *P* < 0.05; Figure 3C), clinical stage (stage 1 *vs* stage 2, stage 1 *vs* stage 3 and stage 1 *vs* stage 4, *P* < 0.05; Figure 3D) and T stage (T1 *vs* T2, T1 *vs* T3 and T1 *vs* T4, *P* < 0.05; Figure 3E) of patients. In addition, a heat map(Figure 3G) was associated with clinicopathological features, and a significant relationship was observed between *BCYRN1* expression and the pathological grade (*P* < 0.05), clinical stage (*P* < 0.001) and T stage (*P* < 0.0001) of patients.

***Analyses of independent prognostic markers for survival and establishment of nomogram prediction model***

To confirm the prognostic significance of *BCYRN1* in HCC patients, univariate (Figure 4A) and multivariate regression analyses (Figure 4B) of prognostic markers in HCC patients were completed. The results of univariate and multivariate prognostic analysis were consistent, thereby suggesting that the expression of *BCYRN1* (HR = 1.16, *P* = 0.038) and the clinical stage (HR = 1.543, *P* < 0.001) of the tumor were significantly associated with OS in patients and could be used as independent prognostic markers for HCC. A nomogram prediction model (Figure 4C) for survival prediction in HCC patients was constructed using clinicopathological information and survival prognosis of patients. According to the clinicopathological information and the expression level of *BCYRN1*, the 5-year, 3-year and 1-year survival rates of patients can be predicted. Finally, calibration curves were drawn(Figure 4D) to evaluate the accuracy of the prediction model. Because the inclination of the prediction curves was close to the diagonal, the prediction model was reliable and accurate.

***Analysis of co-expressed vs DEGs for BCYRN1 in HCC***

An analysis of co-expressed genes of *BCYRN1* was performed. Among them, co-expressed genes that satisfied “*P* < 0.001 and correlation coefficient > 0.5” were screened to obtain a total of eight genes, and the co-expression correlation scatter plot was plotted (Supplementary Figure 1). The co-expression results were used to select the 11 genes that most closely were related to co-expression, and a co-expression circle plot was drawn (Figure 5A), in which red represented a positive correlation (*LGALS1*, *TMSB4XP4*, *TMSB10*, *CCL26*, *S100A11*, *IMPDH1*), green represented a negative correlation (*PAH*, *SLC2A2*, *F12*, *HNF4A*, *CPB2*), and the shaded area represented the magnitude of the correlation. Finally, the DEGs between groups with high and low *BCYRN1* expression were explored, and 50 DEGs were selected that were most significantly upregulated and downregulated. Finally, a heat map of DEGs was drawn (Figure 5B).

***GO, KEGG and GSEA enrichment analysis***

A total of 1453 (GO) and 622 (KEGG) DEGs associated with *BCYRN1* were screened using HCC expression data from the TCGA database. Next, these DEGs were subjected to GO and KEGG enrichment analyses. GO enrichment analysis revealed that these genes were primarily involved in biological processes, including extracellular structure organization, external encapsulating structure organization and extracellular matrix organization. Cellular composition included collagen-containing extracellular matrix, the ion channel complex and the synaptic membrane. The molecular functions performed mainly involved gated channel activity, ion channel activity and signaling receptor activator activity, *etc* (Figure 6A-C). KEGG enrichment analysis indicated that the DEGs of *BCYRN1* primarily involved pathways, including neuroactive ligand-receptor interaction, extracellular matrix-receptor interaction and protein digestion and absorption, among which protein digestion and absorption were pathways with the most annotated genes (Figure 6D and E). Finally, the result of GSEA enrichment analysis showed that pathways or functions that may be active in the low *BCYRN1* expression group were as follows: retinol metabolism, glycine, serine and threonine metabolism, peroxisome, primary bile acid biosynthesis and fatty acid metabolism (Figure 6F).

***Correlation analysis and differential analysis between BCYRN1 expression, TME and immune cell infiltration in HCC***

Stromal cell and immune cell scores in groups with high and low *BCYRN1* expression were evaluated, and violin plots of TME scores were plotted based on the results. The data showed that immune cell score, stromal cell score and ESTIMATEScore in the group with high *BCYRN1* expression were significantly higher compared to those in the low expression group (*P* < 0.05), showing that the immune cell and stromal cell content in the group with high *BCYRN1* expression in HCC was higher (Figure 7A). Differential analysis of immune cells was performed, and the results demonstrated that the levels of plasma cells (*P* < 0.05) and CD8 T cells (*P* < 0.001) were significantly increased in the group with low *BCYRN1* expression. Moreover, the level of macrophages M0 (*P* < 0.05) was significantly increased in the group with high *BCYRN1* expression (Figure 7B). Finally, correlation analysis was performed between various immune cells and *BCYRN1* expression, and correlation Lollipop and correlation scatter plots were plotted. The results showed that *BCYRN1* expression was positively linked with the level of macrophages M0 (*P* = 0.016), macrophages M2 (*P* = 0.0094) and regulatory T cells (*P* = 0.018) and negatively correlated with the level of plasma cells (*P* = 0.012) and CD8 T cells (*P* = 0.0069)(Figure 7C and Supplementary Figure 2).

***Correlation analysis of BCYRN1 expression with immune checkpoint genes and TMB***

Immune checkpoint genes associated with *BCYRN1* expression were explored, and circular correlation heat maps (Figure 8A) as well as rectangular correlation heat maps (Figure 8B) were plotted. The results showed that 19 immune checkpoint-related genes (*LAIR1*, *CD70*, *TNFRSF4*, *PDCD1LG2*, *HAVCR2*, *CTLA4*, *TNFSF15*, *CD276*, *LGALS9*, *TNFRSF18*, *TNFRSF9*, *TNFRSF14*, *CD44*, *CD80*, *CD86*, *CD200R1*, *TNFRSF8*, *TNFSF9*, *VTCN1*) were significantly and positively correlated with *BCYRN1* expression, and one immune checkpoint-related gene (*ADORA2A*) was significantly and negatively correlated with *BCYRN1* expression. The relationship between *BCYRN1* expression and TMB was also investigated, and correlation scatterplots were plotted (Figure 8C). Together, the data revealed that there was no significant relationship between TMB and *BCYRN1* expression (*P* = 0.11).

***Differential analysis of BCYRN1 expression with chemosensitivity and immunotherapy efficacy***

Chemotherapy is a promising therapeutic option for liver cancer. The IC50 of commonly used chemotherapeutic agents was evaluated in groups with high and low *BCYRN1* expression, and difference boxplots were plotted (Figure 9A). The results showed that CGP-60474, S-Trityl-L-cysteine, sunitinib, paclitaxel, VX-680 and pyrimethamine had higher sensitivity and a better therapeutic effect in the high *BCYRN1* expression group. Progression of immune checkpoint inhibitors changes the prognosis of HCC patients, and CTLA-4 and PD-1 are critical indicators to determine their therapeutic effects. Therefore, the therapeutic effects of anti-PD-1 and anti-CTLA-4 were scored in groups with high and low *BCYRN1* expression. The data revealed that the immunotherapeutic effect of anti-PD-1 was not significantly correlated (*P* = 0.071) with the expression of *BCYRN1*, while the immunotherapeutic effect of anti-CTLA-4 was more effective in the group with low *BCYRN1* expression (*P* = 0.012; Figure 9B).

***Screening method for the literature and features of the included literature***

Preliminary searches of three English databases yielded the following results: PubMed (*n* = 9), Embase (*n* = 7) and Web of Science (*n* = 16). Retrieval results were imported into Endnote. After removing duplicate studies, the remaining studies (*n* = 17) were analyzed. By reading the abstract and title, studies not conforming to the literature type and unrelated studies (*n* = 11) were removed. The remaining six articles were downloaded in full, and after careful examination, three publications were excluded because of a lack of essential data and poor quality. The remaining three studies were eventually included in our meta-analysis. Figure 10 depicts the above-mentioned search flowchart. All three studies were written in English, and all were from China. Specimen types were all HCC tissues, RNA expression was determined by qRT-PCR, and the source of HR values was indirectly calculated from OS curves. Follow-up time was 50 mo, 80 mo and 120 mo. NOS scores ranged from a minimum of 7 to a maximum of 8, all of which were higher quality articles. Table 1 shows essential features of the collected articles.

***Relationship between BCYRN1 expression and the prognosis of HCC patients***

Because there was no obvious heterogeneity (*I*2 = 0.0%, *P* = 0.874) across studies, a fixed effects model was selected to combine the data. The forest plot results (HR = 1.66, 95%CI: 1.15-2.39; Figure 11) showed that *BCYRN1* overexpression was related to a poor prognosis in HCC patients, with individuals in the high *BCYRN1* expression group having a poorer prognosis and shorter survival. Because only three studies were included, a bias test and sensitivity analysis were not performed.

**DISCUSSION**

HCC is one of the most prevalent types of cancer of the digestive system. Its early symptoms are not clear, and the main characteristics of the middle and advanced stages are rapid progression, unsatisfactory treatment outcomes and low 5-year survival rates[31]. The development of HCC is an extremely complex process and includes the involvement of multiple genes and the evolution of multiple steps. Its possible underlying molecular mechanisms remain elusive. In recent years, with the discovery and exploration of lncRNAs, it has been demonstrated that lncRNAs play an important role in the development and progression of HCC[32]. Previous studies have shown that lncRNA can regulate signaling pathways associated with HCC and the expression levels of downstream target genes, thereby further affecting the activity of proteins by changing the expression levels and stability of mRNAs and miRNAs, which are closely related to a variety of malignant phenotypes of HCC[33,34]. Dysregulation of lncRNAs has been associated with precancerous lesions of HCC, such as hepatitis B virus infection, cirrhosis and fatty liver[35]. LncRNA can also evaluate and predict the efficacy of various treatment modalities for HCC patients and has a wide range of applications in HCC diagnosis and treatment[36]. *BCYRN1* is an important member of the lncRNA family and exploring its prognostic value and therapeutic prospects in HCC is a main goal.

Our study first investigated the expression level of *BCYRN1* in pan-cancer and normal tissues, and discovered that it was highly expressed in BRCA, LUAD, ESCA, LUSC, WT, STES, STAD, LIHC, SKCM, PAAD, OV, UCS, KICH, ALL, TGCT, CHOL and LAML, and lowly expressed in GBM, GBMLGG, KIRP, KIPAN, KIRC, THCA and ACC. The expression of *BCYRN1* in HCC was independently examined, and the results revealed that *BCYRN1* was considerably overexpressed in tumors. These early findings imply that *BCYRN1* might be an oncogene in HCC. Our study continued to focus on the association between *BCYRN1* expression and the prognosis and clinicopathological features of HCC patients. Using the GEPIA database and the TCGA dataset, KM curves for survival outcomes (including OS, DFS and PFS) were generated, all of which indicated that patients with high *BCYRN1* expression had a poorer prognosis. ROC curves showed that *BCYRN1* was of great value in predicting patient prognosis.

Clinicopathologic analysis showed that *BCYRN1* expression was substantially linked with the clinical stage, pathological grade and T stage of HCC patients, and *BCYRN1* expression was higher when the clinical stage was more advanced, the pathological grade was worse and the T stage was higher. Our findings showed that the worse the pathological grade, then the stronger the proliferation and invasiveness of HCC and the higher the expression level of *BCYRN1*. However, the expression of stage G4 in Figure 3C is low, which is not in line with the expected results. The reasons behind it have been thoroughly explored. As shown by the downloaded clinical data, there were 54 patients in the G1 stage, 179 patients in the G2 stage, and 123 patients in the G3 stage, while only 13 patients were in the G4 stage. Therefore, the number of patients in the G4 stage was significantly lower than those in other stages, and the sample size was too small to be representative. Given a sufficient sample size, the results are estimated to be in line with the expectations.

Subsequently, univariate and multivariate Cox regression analysis showed that the expression of *BCYRN1* and the clinical stage of the tumor were independent prognostic factors for HCC patients. Therefore, we developed a nomogram prediction model that can predict OS in patients based on their clinicopathological characteristics and *BCYRN1* expression. According to the results of the above-mentioned study, overexpression of *BCYRN1* is related with a poor prognosis in patients and is likely to be an independent prognostic marker in HCC patients.

In addition, co-expressed genes and DEGs associated with *BCYRN1* were screened. The most strongly correlated co-expressed genes were *LGALS1*, *TMSB4XP4*, *TMSB10*, *CCL26*, *S100A11*, *IMPDH1*, *PAH*, *SLC2A2*, *F12*, *HNF4A*, and *CPB2*. Among them, genes that were positively correlated with the expression of *BCYRN1* were generally oncogenes and can lead to poor prognosis in HCC. For example, it has been found that the *LGALS1* gene is upregulated in HCC and can encode related proteins, thereby increasing tumor migration and invasion[37]. Similarly, *TMSB10* expression in HCC was significantly higher compared to that in surrounding normal liver tissues, and high TMSB10 expression was significantly associated with tumor volume and distant metastasis, which was a potential prognostic marker for predicting HCC patients[38]. It has previously been revealed that *CCL26* acts on fibroblasts, thereby affecting processes including proliferation, invasion and angiogenesis in HCC[39]. *S100A11* overexpression in HCC can enhance HCC invasiveness[40]. In contrast, genes negatively correlated with *BCYRN1* expression are generally tumor suppressor genes. Low *SLC2A2* expression was correlated with a worse DFS and OS in HCC patients, and *SLC2A2* expression was negatively associated with the degree of immune infiltration in HCC[41]. Furthermore, it has been demonstrated that *HNF4A* can inhibit the motility and metastasis of HCC cells[42]. The above-mentioned studies demonstrated the value of co-expression analysis of genes.

Moreover, DEGs associated with *BCYRN1* were screened, and KEGG, GO and Gene Set Enrichment Analysis enrichment analysis were performed. The results of comprehensive enrichment analysis demonstrated that the primary functions of *BCYRN1*-related DEGs were to regulate extracellular matrix components, regulate ion channel activity and signal molecule transmission, such as synaptic membrane. In addition, *BCYRN1*-related DEGs were involved in protein digestion and absorption as well as the metabolism of retinol, amino acids and fatty acids and involved in the regulation of tumor-related pathways (calcium signaling pathway, Wnt signaling pathway, IL-17 signaling pathway). The TME consists of three parts, including the extracellular matrix, stromal cells and cell growth factors. The extracellular matrix is crucial in the formation of tumors[43,44]. It has been demonstrated that dysregulation of the Ca2 + concentration increases the risk of tumor development and accelerates tumor progression, whereas inactivation of Ca2+ channels accelerates the proliferation and growth of tumor cells[45]. The Wnt signaling pathway can regulate cell proliferation, differentiation, apoptosis and stem cell renewal, and dysregulation of the Wnt signaling pathway can occur at all stages of malignant tumors[46]. The above-mentioned studies and analyses on the mechanism of *BCYRN1* involved in HCC showed that *BCYRN1* is a very important regulatory gene in the formation and progression of HCC and an important possible therapeutic target for HCC.

Mechanistic studies of *BCYRN1* in HCC could validate the conclusions of the current study. It has been proven that *BCYRN1* is highly expressed in HCC and is associated with a poor prognosis in HCC patients. Together, *BCYRN1*, *POU3F2*, and miR490-3p constitute a network of competing endogenous RNAs that regulate the migration, invasion and proliferation of HCC[26]. Liu *et al*[47] discovered that *BCYRN1* can enhance the invasion and proliferation of HCC by regulating the *BCYRN1*/*BATF*/*TM4SF1* targeting axis. Moreover, Lin *et al*[48] showed that *BCYRN1* is overexpressed in HCC and promotes the growth of HCC cells and the formation of tumor tissues by regulating cell cycle-related genes and stemness markers, and prevents the degradation of cyclin E2 mRNA. Through *in vivo* and *in vitro* experiments, Tan *et al*[27] showed that *BCYRN1* could affect expression of the c-MYC protein, thereby affecting the levels of apoptotic and anti-apoptotic proteins and promoting the progression of HCC. Combined, these studies strongly confirmed that *BCYRN1* is indeed a possible therapeutic target as well as a prognostic marker for HCC.

The TME refers to the complex multicellular environment in which tumors are located during growth and development[49]. The TME is usually composed of three parts, including immune cells, the extracellular matrix and secreted factors and stromal cells, which are mixed with lymphatic vessels and blood vessels to regulate and influence the occurrence and development of tumor cells[50]. In the TME, various immune cells play different roles during antitumor immunotherapy, especially T cells *vs* B cells[51]. The relationship between the expression level of *BCYRN1* and the TME score was investigated. The results showed that the *BCYRN1* high expression group had a higher TME score, a higher level of immune and stromal cells and a lower purity of tumors. In addition, the relationship between *BCYRN1* expression and the level of various immune cells was investigated, and the results showed that the content of CD8 T cells and plasma cells was higher in the group with low expression, while the number of macrophages M0 was higher in the group with high expression. Thus, *BCYRN1* expression is linked to the level of M0 and M2 macrophages, CD8 T cells and plasma cells, and *BCYRN1* can regulate the level of the above-mentioned immune cells.

Finally, the connection between *BCYRN1* expression and drug sensitivity was also investigated. It was discovered that six drugs were more sensitive in the group with high expression of *BCYRN1*, thus providing a novel idea for clinical medication. PD-1 and CTLA-4 are important immunotherapeutic targets[52]. The differences in efficacy between these two immunotherapies were analyzed in the high and low *BCYRN1* expression groups, and the results showed that the therapeutic effect of anti-CTLA-4 was more pronounced in the low *BCYRN1* expression group. Thus, our data showed that *BCYRN1* may have great potential in immunotherapy.

Our study has the following limitations. First, data were downloaded from the online database TCGA and were not validated by the laboratory and clinic. Second, although the sample size of the TCGA database is large, the type of database is relatively single. To compensate for the above-mentioned shortcomings, the meta-analysis was performed, which combined all survival prognosis studies of *BCYRN1* in HCC and showed that high expression of *BCYRN1* in HCC was significantly associated with poor patient prognosis, which was consistent with the conclusions of the bioinformatics. The prognostic value and immunotherapeutic prospects of *BCYRN1* in HCC were explored by bioinformatics and meta-analysis, and valuable conclusions were drawn. To further explore the function and underlying mechanism of *BCYRN1* in HCC, more in-depth clinical and laboratory studies are required.

**CONCLUSION**

Our study revealed that the expression level of *BCYRN1* in HCC tissues was significantly higher compared to that in surrounding normal liver tissues and that high *BCYRN1* expression was related to a poor prognosis and clinicopathological progression of HCC patients. Furthermore, the expression of *BCYRN1* was significantly related to the level of immune cell infiltration, drug sensitivity and immunotherapy responses in HCC. Therefore, *BCYRN1* is likely to be a prognostic indicator and a target for the treatment in HCC patients. The prognostic value of *BCYRN1* and the promise of immunotherapy need to be further confirmed by large clinical and laboratory studies.

**ARTICLE HIGHLIGHTS**

***Research background***

Hepatocellular carcinoma (HCC) is one of the most common types of cancer worldwide and has a high mortality rate. Early detection of HCC can achieve a good 5-year survival rate by surgical treatment, liver transplantation and radiotherapy. Therefore, early diagnosis and treatment is particularly important, and identifying novel sensitive tumor markers and discovering novel molecular therapeutic targets are key goals. Exploring novel immunotherapeutic drugs is another breakthrough.

***Research motivation***

The expression of brain cytoplasmic RNA1 (*BCYRN1*) is linked to the clinicopathology and prognosis of several types of cancers, among which HCC is one of the most frequent types of cancer worldwide.

***Research objectives***

In this study, bioinformatics and meta-analysis were used to explore the prognostic value and immunotherapeutic potential of *BCYRN1* in HCC.

***Research methods***

Information was obtained from the Cancer Genome Atlas database. First, the correlation between *BCYRN1* expression and prognosis and clinicopathologic characteristics of HCC patients was explored. Univariate and multivariate regression analyses were employed to examine the relationship between *BCYRN1* and HCC prognosis. Second, potential functions and pathways were explored by means of enrichment analysis of differentially-expressed genes. The relationship between *BCYRN1* expression and tumor microenvironment, immune cell infiltration, immune checkpoint, drug sensitivity and immunotherapy effect was also investigated. Finally, three major databases were searched and used to conduct a meta-analysis on the relationship between *BCYRN1* expression and patient prognosis.

***Research results***

*BCYRN1* expression was significantly higher in HCC compared to normal tissues and was linked to a poor prognosis and clinicopathological characteristics. Enrichment analysis showed that *BCYRN1* regulates the extracellular matrix and transmission of signaling molecules, participates in the metabolism of nutrients, such as proteins, and participates in tumor-related pathways. *BCYRN1* expression was linked to the tumor microenvironment, immune cell infiltration, drug sensitivity and the efficacy of immunotherapy. Furthermore, the meta-analysis in this study showed that *BCYRN1* overexpression was related to a worse outcome in HCC patients.

***Research conclusions***

Our study revealed that high *BCYRN1* expression related to a poor prognosis and clinicopathological progression of HCC patients. Furthermore, the expression of *BCYRN1* was significantly related to the level of immune cell infiltration, drug sensitivity and immunotherapy responses in HCC.

***Research perspectives***

Overexpression of *BCYRN1* relates to poor prognosis and may be a potential prognostic factor and immunotherapeutic target in HCC.

**ACKNOWLEDGEMENTS**

We appreciate the help of the RCA citation tool (<https://www.referencecitationanalysis.com/>) in improving our article.

**REFERENCES**

1 **Vogel A**, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. *Lancet* 2022; **400**: 1345-1362 [PMID: 36084663 DOI: 10.1016/S0140-6736(22)01200-4]

2 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]

3 **Siegel RL**, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin* 2022; **72**: 7-33 [PMID: 35020204 DOI: 10.3322/caac.21708]

4 **Roayaie S**, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, Schwartz M, Han G, Izzo F, Chen M, Blanc JF, Johnson P, Kudo M, Roberts LR, Sherman M. The role of hepatic resection in the treatment of hepatocellular cancer. *Hepatology* 2015; **62**: 440-451 [PMID: 25678263 DOI: 10.1002/hep.27745]

5 **European Association for the Study of the Liver**. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. *J Hepatol* 2018; **69**: 154-181 [PMID: 29628280 DOI: 10.1016/j.jhep.2018.03.018]

6 **Cheng AL**, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. *J Hepatol*2020; **72**: 307-319 [PMID: 31954494 DOI: 10.1016/j.jhep.2019.09.025]

7 **Greten TF**, Lai CW, Li G, Staveley-O'Carroll KF. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. *Gastroenterology* 2019; **156**: 510-524 [PMID: 30287171 DOI: 10.1053/j.gastro.2018.09.051]

8 **Huynh NP**, Anderson BA, Guilak F, McAlinden A. Emerging roles for long noncoding RNAs in skeletal biology and disease. *Connect Tissue Res* 2017; **58**: 116-141 [PMID: 27254479 DOI: 10.1080/03008207.2016.1194406]

9 **Gugnoni M**, Ciarrocchi A. Long Noncoding RNA and Epithelial Mesenchymal Transition in Cancer. *Int J Mol Sci* 2019; **20** [PMID: 31003545 DOI: 10.3390/ijms20081924]

10 **Anastasiadou E**, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. *Nat Rev Cancer* 2018; **18**: 5-18 [PMID: 29170536 DOI: 10.1038/nrc.2017.99]

11 **Geisler S**, Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. *Nat Rev Mol Cell Biol* 2013; **14**: 699-712 [PMID: 24105322 DOI: 10.1038/nrm3679]

12 **Eptaminitaki GC**, Wolff N, Stellas D, Sifakis K, Baritaki S. Long Non-Coding RNAs (lncRNAs) in Response and Resistance to Cancer Immunosurveillance and Immunotherapy. *Cells* 2021; **10** [PMID: 34943820 DOI: 10.3390/cells10123313]

13 **Slack FJ**, Chinnaiyan AM. The Role of Non-coding RNAs in Oncology. *Cell* 2019; **179**: 1033-1055 [PMID: 31730848 DOI: 10.1016/j.cell.2019.10.017]

14 **Wells AC**, Pobezinskaya EL, Pobezinsky LA. Non-coding RNAs in CD8 T cell biology. *Mol Immunol* 2020; **120**: 67-73 [PMID: 32085976 DOI: 10.1016/j.molimm.2020.01.023]

15 **Ghafouri-Fard S**, Dashti S, Hussen BM, Farsi M, Taheri M. BCYRN1: An oncogenic lncRNA in diverse cancers. *Pathol Res Pract* 2021; **220**: 153385 [PMID: 33647864 DOI: 10.1016/j.prp.2021.153385]

16 **Han X**, Wang Y, Zhao R, Zhang G, Qin C, Fu L, Jin H, Jiang X, Yang K, Cai H. Clinicopathological Significance and Prognostic Values of Long Noncoding RNA BCYRN1 in Cancer Patients: A Meta-Analysis and Bioinformatics Analysis. *J Oncol* 2022; **2022**: 8903265 [PMID: 35874631 DOI: 10.1155/2022/8903265]

17 **Hu T**, Lu YR. BCYRN1, a c-MYC-activated long non-coding RNA, regulates cell metastasis of non-small-cell lung cancer. *Cancer Cell Int* 2015; **15**: 36 [PMID: 25866480 DOI: 10.1186/s12935-015-0183-3]

18 **Zhai H**, Li Y. BCYRN1 is correlated with progression and prognosis in gastric cancer. *Biosci Rep* 2019; **39** [PMID: 31652309 DOI: 10.1042/BSR20190505]

19 **Ren H**, Yang X, Yang Y, Zhang X, Zhao R, Wei R, Zhang X, Zhang Y. Upregulation of LncRNA BCYRN1 promotes tumor progression and enhances EpCAM expression in gastric carcinoma. *Oncotarget* 2018; **9**: 4851-4861 [PMID: 29435146 DOI: 10.18632/oncotarget.23585]

20 **Zheng H**, Chen C, Luo Y, Yu M, He W, An M, Gao B, Kong Y, Ya Y, Lin Y, Li Y, Xie K, Huang J, Lin T. Tumor-derived exosomal BCYRN1 activates WNT5A/VEGF-C/VEGFR3 feedforward loop to drive lymphatic metastasis of bladder cancer. *Clin Transl Med* 2021; **11**: e497 [PMID: 34323412 DOI: 10.1002/ctm2.497]

21 **Huo W**, Qi F, Wang K. Long non‑coding RNA BCYRN1 promotes prostate cancer progression via elevation of HDAC11. *Oncol Rep* 2020; **44**: 1233-1245 [PMID: 32705287 DOI: 10.3892/or.2020.7680]

22 **Wu K**, Xu K, Liu K, Huang J, Chen J, Zhang J, Zhang N. Long noncoding RNA BC200 regulates cell growth and invasion in colon cancer. *Int J Biochem Cell Biol*2018; **99**: 219-225 [PMID: 29625226 DOI: 10.1016/j.biocel.2018.04.001]

23 **Yang L**, Zhang Y, Bao J, Feng JF. Long non-coding RNA BCYRN1 exerts an oncogenic role in colorectal cancer by regulating the miR-204-3p/KRAS axis. *Cancer Cell Int* 2020; **20**: 453 [PMID: 32944001 DOI: 10.1186/s12935-020-01543-x]

24 **Chen L**, Shi Q, Fan B, Cai Y. Role of lncRNA BCYRN1 in trophoblast cell physiology and pathogenesis of preeclampsia. *Exp Ther Med* 2021; **22**: 1137 [PMID: 34466147 DOI: 10.3892/etm.2021.10571]

25 **Gu L**, Lu L, Zhou D, Liu Z. Long Noncoding RNA BCYRN1 Promotes the Proliferation of Colorectal Cancer Cells via Up-Regulating NPR3 Expression. *Cell Physiol Biochem* 2018; **48**: 2337-2349 [PMID: 30114690 DOI: 10.1159/000492649]

26 **Ding S**, Jin Y, Hao Q, Kang Y, Ma R. LncRNA BCYRN1/miR-490-3p/POU3F2, served as a ceRNA network, is connected with worse survival rate of hepatocellular carcinoma patients and promotes tumor cell growth and metastasis. *Cancer Cell Int* 2020; **20**: 6 [PMID: 31920461 DOI: 10.1186/s12935-019-1081-x]

27 **Tan N**, Zhu B, Shu H, Tao YF, Wu JR, Fang M, Li CR, Chen ZQ, Ou C. Effect of lncRNA‑BC200 on proliferation and migration of liver cancer cells in vitro and in vivo. *Oncol Rep* 2020; **43**: 461-470 [PMID: 31894342 DOI: 10.3892/or.2019.7447]

28 **Ming XL**, Feng YL, He DD, Luo CL, Rong JL, Zhang WW, Ye P, Chai HY, Liang CZ, Tu JC. Role of BCYRN1 in hepatocellular carcinoma pathogenesis by lncRNA-miRNA-mRNA network analysis and its diagnostic and prognostic value. *Epigenomics* 2019; **11**: 1209-1231 [PMID: 31339046 DOI: 10.2217/epi-2018-0218]

29 **Booy EP**, McRae EK, Koul A, Lin F, McKenna SA. The long non-coding RNA BC200 (BCYRN1) is critical for cancer cell survival and proliferation. *Mol Cancer* 2017; **16**: 109 [PMID: 28651607 DOI: 10.1186/s12943-017-0679-7]

30 **Liberati A**, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009; **339**: b2700 [PMID: 19622552 DOI: 10.1136/bmj.b2700]

31 **Zhou F**, Shang W, Yu X, Tian J. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. *Med Res Rev* 2018; **38**: 741-767 [PMID: 28621802 DOI: 10.1002/med.21455]

32 **Xie C**, Li SY, Fang JH, Zhu Y, Yang JE. Functional long non-coding RNAs in hepatocellular carcinoma. *Cancer Lett* 2021; **500**: 281-291 [PMID: 33129957 DOI: 10.1016/j.canlet.2020.10.042]

33 **Lim LJ**, Wong SYS, Huang F, Lim S, Chong SS, Ooi LL, Kon OL, Lee CG. Roles and Regulation of Long Noncoding RNAs in Hepatocellular Carcinoma. *Cancer Res*2019; **79**: 5131-5139 [PMID: 31337653 DOI: 10.1158/0008-5472.CAN-19-0255]

34 **Yuan D**, Chen Y, Li X, Li J, Zhao Y, Shen J, Du F, Kaboli PJ, Li M, Wu X, Ji H, Cho CH, Wen Q, Li W, Xiao Z, Chen B. Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis. *Int J Biol Sci* 2021; **17**: 220-235 [PMID: 33390845 DOI: 10.7150/ijbs.50730]

35 **Sarfaraz N**, Somarowthu S, Bouchard MJ. The interplay of long noncoding RNAs and hepatitis B virus. *J Med Virol* 2023; **95**: e28058 [PMID: 35946066 DOI: 10.1002/jmv.28058]

36 **Sheng J**, Lv E, Xia L, Huang W. Emerging roles and potential clinical applications of long non-coding RNAs in hepatocellular carcinoma. *Biomed Pharmacother*2022; **153**: 113327 [PMID: 35779423 DOI: 10.1016/j.biopha.2022.113327]

37 **Spano D**, Russo R, Di Maso V, Rosso N, Terracciano LM, Roncalli M, Tornillo L, Capasso M, Tiribelli C, Iolascon A. Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. *Mol Med* 2010; **16**: 102-115 [PMID: 20200618 DOI: 10.2119/molmed.2009.00119]

38 **Song C**, Su Z, Guo J. Thymosin β 10 is overexpressed and associated with unfavorable prognosis in hepatocellular carcinoma. *Biosci Rep* 2019; **39** [PMID: 30787051 DOI: 10.1042/bsr20182355]

39 **Lin ZY**, Chuang YH, Chuang WL. Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells. *Biomed Pharmacother* 2012; **66**: 525-529 [PMID: 22739041 DOI: 10.1016/j.biopha.2012.02.001]

40 **Luo X**, Xie H, Long X, Zhou M, Xu Z, Shi B, Jiang H, Li Z. EGFRvIII mediates hepatocellular carcinoma cell invasion by promoting S100 calcium binding protein A11 expression. *PLoS One* 2013; **8**: e83332 [PMID: 24376686 DOI: 10.1371/journal.pone.0083332]

41 **Peng Q**, Hao LY, Guo YL, Zhang ZQ, Ji JM, Xue Y, Liu YW, Lu JL, Li CG, Shi XL. Solute carrier family 2 members 1 and 2 as prognostic biomarkers in hepatocellular carcinoma associated with immune infiltration. *World J Clin Cases* 2022; **10**: 3989-4019 [PMID: 35665115 DOI: 10.12998/wjcc.v10.i13.3989]

42 **Huang Y**, Xian L, Liu Z, Wei L, Qin L, Xiong Y, Hu L, Zhou S, Fu Q, Li B, Qin Y. AMPKα2/HNF4A/BORIS/GLUT4 pathway promotes hepatocellular carcinoma cell invasion and metastasis in low glucose microenviroment. *Biochem Pharmacol* 2022; **203**: 115198 [PMID: 35940258 DOI: 10.1016/j.bcp.2022.115198]

43 **Théret N**, Bouezzedine F, Azar F, Diab-Assaf M, Legagneux V. ADAM and ADAMTS Proteins, New Players in the Regulation of Hepatocellular Carcinoma Microenvironment. *Cancers (Basel)* 2021; **13** [PMID: 33805340 DOI: 10.3390/cancers13071563]

44 **Carloni V**, Luong TV, Rombouts K. Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever. *Liver Int* 2014; **34**: 834-843 [PMID: 24397349 DOI: 10.1111/liv.12465]

45 **Wang WJ**, Mao LF, Lai HL, Wang YW, Jiang ZB, Li W, Huang JM, Xie YJ, Xu C, Liu P, Li YM, Leung ELH, Yao XJ. Dolutegravir derivative inhibits proliferation and induces apoptosis of non-small cell lung cancer cells via calcium signaling pathway. *Pharmacol Res* 2020; **161**: 105129 [PMID: 32783976 DOI: 10.1016/j.phrs.2020.105129]

46 **Zhou Y**, Xu J, Luo H, Meng X, Chen M, Zhu D. Wnt signaling pathway in cancer immunotherapy. *Cancer Lett* 2022; **525**: 84-96 [PMID: 34740608 DOI: 10.1016/j.canlet.2021.10.034]

47 **Liu Y**, Liu MJ, Jiao M, Jiang LL, Fu X, Wang WJ. Long Noncoding RNA BCYRN1 Recruits BATF to Promote TM4SF1 Upregulation and Enhance HCC Cell Proliferation and Invasion. *Dis Markers* 2022; **2022**: 1561607 [PMID: 35730016 DOI: 10.1155/2022/1561607]

48 **Lin YH**, Wu MH, Huang YH, Yeh CT, Chi HC, Tsai CY, Chuang WY, Yu CJ, Chung IH, Chen CY, Lin KH. Thyroid hormone negatively regulates tumorigenesis through suppression of BC200. *Endocr Relat Cancer* 2018; **25**: 967-979 [PMID: 30400024 DOI: 10.1530/ERC-18-0176]

49 **Bejarano L**, Jordāo MJC, Joyce JA. Therapeutic Targeting of the Tumor Microenvironment. *Cancer Discov* 2021; **11**: 933-959 [PMID: 33811125 DOI: 10.1158/2159-8290.CD-20-1808]

50 **Xiao Y**, Yu D. Tumor microenvironment as a therapeutic target in cancer. *Pharmacol Ther* 2021; **221**: 107753 [PMID: 33259885 DOI: 10.1016/j.pharmthera.2020.107753]

51 **Xie Y**, Xie F, Zhang L, Zhou X, Huang J, Wang F, Jin J, Zhang L, Zeng L, Zhou F. Targeted Anti-Tumor Immunotherapy Using Tumor Infiltrating Cells. *Adv Sci (Weinh)* 2021; **8**: e2101672 [PMID: 34658167 DOI: 10.1002/advs.202101672]

52 **Zhang H**, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, Zeng WJ, Liu Z, Cheng Q. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. *J Exp Clin Cancer Res* 2021; **40**: 184 [PMID: 34088360 DOI: 10.1186/s13046-021-01987-7]

**Footnotes**

**Conflict-of-interest statement:** All authors confirm that there are no conflicts of interest in their study.

**Data sharing statement:** The corresponding author may provide data obtained from this study upon reasonable request.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** November 24, 2022

**First decision:** January 23, 2023

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C, C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Cossiga V, Italy; Qi S, China **S-Editor:** Zhang H **L-Editor:** Filipodia **P-Editor:**


**Figure Legends**

****


**Figure 1 Expression levels of brain cytoplasmic RNA1 in pan-cancer and hepatocellular carcinoma.** A: Expression level of brain cytoplasmic RNA1 (*BCYRN1*) in pan-carcinoma; B: Differential analysis of expression of *BCYRN1* in hepatocellular carcinoma (HCC) tissues compared with normal liver tissues based on the Cancer Genome Atlas database; C: Pairwise difference analysis of *BCYRN1* expression between HCC tissues and surrounding normal liver tissues from the same patient. a*P* < 0.05, b*P* < 0.01, c*P* < 0.001, d*P* < 0.0001.

****


**Figure 2** **Association of brain cytoplasmic RNA1 expression with prognosis in hepatocellular carcinoma patients.** A and B: Association of brain cytoplasmic RNA1 (*BCYRN1*) expression with overall survival (A) and disease-free survival (B) in hepatocellular carcinoma (HCC) patients in the GEPIA2 database; C and D: *BCYRN1* expression in the Cancer Genome Atlas database in relation to overall survival (C) and progression-free (D) survival in HCC patients; E: Receiver operating characteristic curve to assess the predictive value of *BCYRN1* expression with different prognostic years. AUC: Area under the curve; HR: Hazard ratio; TPM: Transcripts per million.

****


**Figure 3 Relationship between expression of brain cytoplasmic RNA1 and clinicopathological characteristics of hepatocellular carcinoma patients.** A: Age; B: Sex (labeled Gender); C: Pathological grade; D: Clinical stage; E: T stage; F: M stage; G: Heat map of the correlation between the expression of brain cytoplasmic RNA1 and clinicopathological features.

****


**Figure 4** **Independent survival prognostic factor analysis and nomogram prediction model.** A: Univariate prognostic analysis; B: Multivariate prognostic analysis; C: Nomogram prediction model; D: Calibration curve of nomogram. *BCYRN1*: Brain cytoplasmic RNA1; OS: Overall survival.

****


**Figure 5** **Co-expressed and differential genes of brain cytoplasmic RNA1 in hepatocellular carcinoma.** A: Co-expression circle plot of 11 genes most closely related to brain cytoplasmic RNA1 (*BCYRN1*) in hepatocellular carcinoma (HCC). Red represented significant positive correlation, green represented significant negative correlation, and shade represented the magnitude of correlation; B: Heat map of differentially expressed genes of *BCYRN1* in HCC. Red represented upregulation and blue represented downregulation. Light blue represented the low expression group of *BCYRN1*, and light red represented the high expression group of BCYRN1.

****


**Figure 6** **Enrichment analysis of brain cytoplasmic RNA1-associated differentially expressed genes.** A: Circle diagram of gene ontology (GO) enrichment analysis in biomolecular function, biological process and cellular component; B: Histogram of GO enrichment analysis; C: Bubble plots for GO enrichment analysis; D: Histogram of Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis showed the top 20 pathways with the most significant correlation; E: Bubble plots for KEGG enrichment analysis; F: Brain cytoplasmic RNA1-associated Gene Set Enrichment Analysis.

****


**Figure 7** **Correlation analysis and differential analysis of brain cytoplasmic RNA1 expression with tumor microenvironment and immune cell infiltration in hepatocellular carcinoma.** A: Violin plot of the difference in tumor microenvironment scores between the high and low brain cytoplasmic RNA1 (*BCYRN1*) expression groups; B: Box plots of differential analysis between the infiltration levels of 22 immune cells and the high and low expression groups of *BCYRN1*; C: Lollipop plot of correlation analysis between expression of *BCYRN1* and levels of 22 immune cell infiltrates. a*P* < 0.05, b*P* < 0.01, c*P* < 0.001.

****


**Figure 8** **Correlation analysis of brain cytoplasmic RNA1 expression with immune checkpoint genes and tumor mutation burden.** A: Circular heatmap of immune checkpoint genes associated with brain cytoplasmic RNA1 (*BCYRN1*) expression; B: Rectangular heat map of immune checkpoint genes associated with *BCYRN1* expression; C: Scatter plot of the correlation between *BCYRN1* expression and tumor mutation burden.

****

**Figure 9 Differential analysis of brain cytoplasmic RNA1 expression with chemosensitivity and immunotherapy efficacy.** A: Box plots of the differences of sensitivity of the six selected chemotherapeutic agents between the high and low expression groups of brain cytoplasmic RNA1 (BCYRN1); B: Violin plot of the difference of immunotherapy effect between the high and low expression groups of BCYRN1.

****

**Figure 10 Flow chart of literature retrieval and screening for meta-analysis.**

****

**Figure 11 Forest plot for meta-analysis of brain cytoplasmic RNA1 expression *vs* overall survival in hepatocellular carcinoma patients.**

**Table 1 Characteristics of studies included in the meta-analysis**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Country** | **Sample size (high/low)** | **Sample** | **Survival analysis** | **Detection method** | **Cutoff value** | **Source of HR values** | **HR and 95%CI** | **Follow-up time** | **NOS score** |
| Ming *et al*[28], 2019 | China | 55 (27/28) | Tissue | OS | qRT-PCR | Median | Survival curves | 2.13 (0.77, 5.93) | 50 mo | 7 |
| Lin *et al*[48], 2018 | China | 240 | Tissue | OS | qRT-PCR | Mean | Survival curves | 1.62 (1.01, 2.59) | 80 mo | 8 |
| Liu *et al*[47], 2022 | China | 100 (50/50) | Tissue | OS | qRT-PCR | NR | Survival curves | 1.56 (0.78, 3.14) | 120 mo | 7 |

HR: Hazard ratio; qRT-PCR: Quantitative real time polymerase chain reaction; OS: Overall survival; NR: Not reported; NOS: Newcastle-Ottawa scale.